10-Aminomethylene-1,8-dihydroxy-9(10H)-anthracenones: Inhibitory action against 5-lipoxygenase and the growth of HaCaT cells

European Journal of Medicinal Chemistry

Volumn 32, Issue 11, 1997, Pages 895-900

  Muller K ^a   Sellmer, A ^b   Prinz, H ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

5 lipoxygenase; Anthracenone; Antiproliferative activity; HaCaT; Vilsmeier

Indexed keywords

10 AMINOMETHYLENE 1,8 DIHYDROXY 9(10H) ANTHRACENONE DERIVATIVE; ANTIPSORIASIS AGENT; ARACHIDONATE 5 LIPOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATTLE; CELL PROLIFERATION; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; KERATINOCYTE; NEUTROPHIL; NONHUMAN; PSORIASIS; STRUCTURE ACTIVITY RELATION;

EID: 0030670951     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(97)82775-4     Document Type: Article

References (27)

1. Kernény L, Ruzicka T, Braun-Falco O (1990) Skin Pharmacol 3, 1-20
2. Müller K (1996) Gen Pharmacol 27, 1325-1335
3. Müller K (1997) Biochem Pharmacol 53, 1215-1221
4. Müller K, Gürster D, Piwek S, Wiegrebe W (1993) J Med Chem 36, 4099-4107
5. Müller K, Leukel P, Ziereis K, Gawlik I (1994) J Med Chem 37, 1660-1669
6. Müller K, Huang HS, Wiegrebe W (1996) J Med Chem 39, 3132-3138
7. Prinz H, Wiegrebe W, Müller K (1996) J Org Chem 61, 2861-2864
8. Sa e Melo T, Dubertret L, Prognon P, Gond A, Mahuzier G, Santus R (1983) J Invest Dermatol 80, 1-6
9. Müller K, Mayer KK, Wiegrebe W (1986) Arch Pharm (Weinheim) 319, 1009-1018
10. Koerner M, Rickborn B (1990) J Org Chem 55, 2662-2672
11. Krishnamurthy S (1982) Tetrahedron Lett 23, 3315-3318
12. Ugi I, Fetzer U, Eholzer U, Knupfer H, Offermann K (1965) Angew Chem 77, 492-504
13. Ford-Hutchinson AW (1991) Potential and therapeutical value of the development of novel 5-lipoxygenase inhibitors. In: Lipoxygenases and Their Products (Cooke ST, Wong A, eds) Academic Press, London, 137-160
14. Müller K (1994) Arch Pharm (Weinheim) 327, 3-19
15. Ford-Hutchinson AW (1989) Evidence for the involvement of leukotrienes and other lipoxygenase products in disease states. In: Leukotrienes and Lipoxygenases (Rokach J, ed) Elsevier, Amsterdam, 405-25
16. Ziboh VA (1988) Drug Dev Res 13, 137-146
17. Klem EB (1978) J Invest Dermatol 70 27-32
18. Boukamp P, Petrussevska RT, Breìtkreutz D, Hornung J, Markham A, Fusening NE (1988) J Cell Biol 761,761-771
19. Nelson MJ, Batt DG, Thompson JS, Wright SW (1991) J Biol Chem 266, 8225-8229
20. Percival MD (1991) J Biol chem 266, 10058-10061
21. Hammond ML, Zambias RA, Chang MN, Jensen NP, McDonald J, Thompson K, Boulton DA, Kopka IE, Hand KM, Opas EE, Luell S, Bach T, Davies P, MacIntyre DE, Bonney RJ, Humes JL (1990) J Med Chem 33, 908-918
22. Kragballe K, Desjarlais L, Voorhees JJ (1985) Br J Dermatol 113, 43-52
23. Chan CC, Duhamel L, Ford-Hutchison A (1985) J Invest Dermatol 85, 333-334
24. Janssen-Timmen U, Vickers PJ, Wittig U, Lehmann WD, Stark HJ, Fusening NE, Rosenbach T, Rådmark O, Samuelsson B, Habenicht AJR (1995) Proc Natl Acad Sci USA 92, 6966-6970
25. Carter RE (1968) Acta Chem Scand 22, 2643-2652
26. Pettit GR, Kalnins MV, Liu TMH, Thomas EG, Parent K (1961) J Org Chem 26, 2563-2566
27. Boyer JH, Ramakrishnan VT (1972) J Org Chem 37, 1360-1364